arrow
G

Glenn Heller

Memorial Sloan Kettering Cancer Center
H指数:100
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

给予雄激素受体途径抑制剂的转移性去势抵抗性前列腺癌患者的克隆造血和临床结局 (联盟A031201)

2024-09-180
PRE
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
2024-06-281
PRE
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors (Vol 26, pg 453, 2008)
2024-03-260
OA
The ectonucleotidase CD39 identifies tumor-reactive CD8+T cells predictive of immune checkpoint blockade efficacy in human lung cancer

外核酸酶CD39识别肿瘤反应性CD8 T细胞,预测人类肺癌中免疫检查点阻断功效

IMMUNITY
IF26.3
2023-01-0146
PRE
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
2021-12-2818
OA
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
2021-12-0111
OAAI
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
2020-01-06169
OA
Genomic correlates of clinical outcome in advanced prostate cancer

晚期前列腺癌临床预后的基因组相关性

2019-05-06901
OAAI